Corporate Profile

Zura Bio Limited is a clinical-stage biotechnology company advancing immunology assets into Phase 2 development programs, including ZB-168 and torudokimab. ZB-168 is an anti IL7R α inhibitor that has the potential to impact diseases driven by IL7 and TSLP biological pathways. Zura aims to develop a portfolio of therapeutic indications for ZB-168 which build on existing Phase 1b data in Type 1 Diabetes demonstrating a favorable safety profile and strong biological rationale. Torudokimab is a fully human, high affinity monoclonal antibody that neutralizes IL33 and is currently at the Phase 2 clinical development stage.

Data Provided by Refinitiv. Minimum 15 minutes delayed.

Events

Investor events will be posted soon

SEC Filings

Statement of changes in beneficial ownership of securities

4

Statement of changes in beneficial ownership of securities

4

Statement of changes in beneficial ownership of securities

4